

Giuseppe Luigi Banna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7546629/giuseppe-luigi-banna-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

2,776
citations

25
h-index

48
g-index

146
ext. papers

3,766
ext. citations

5.9
avg, IF

5.37
L-index

#	Paper	IF	Citations
126	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
125	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
124	Standard versus high-dose chemotherapy in mediastinal germ cell tumors: a narrative review.. <i>Mediastinum</i> , 2022 , 6, 6	0.5	
123	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079580	5.4	0
122	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials.. <i>European Journal of Cancer</i> , 2022 , 166, 287-299	7.5	1
121	Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.. <i>Current Oncology Reports</i> , 2022 , 1	6.3	0
120	A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 915 PROMISE-meso phase III trial. <i>Lung Cancer</i> , 2022 , 169, 77-83	5.9	
119	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. <i>Cancers</i> , 2021 , 13,	6.6	3
118	Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. <i>Immunotherapy</i> , 2021 , 13, 1379-1386	3.8	0
117	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	16
116	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103241	7	5
115	Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
114	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 2021 , 9,		20
113	KRAS G12C Mutations in NSCLC: From Target to Resistance. <i>Cancers</i> , 2021 , 13,	6.6	8
112	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021 , 96, 102179	14.4	17
111	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021 , 148, 24-35	7.5	8
110	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. <i>Immunotherapy</i> , 2021 , 13, 645-652	3.8	1

109	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021 , 150, 224-231	7.5	8
108	Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3385-3400	4.4	0
107	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. <i>Clinical Lung Cancer</i> , 2021 , 22, e180-e192	4.9	5
106	ADAURA: Mature Enough for Publication, Not for Prime Time. <i>Oncologist</i> , 2021 , 26, 266-268	5.7	3
105	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021 , 15, 11795549211021667	1.8	1
104	A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Molecular Pathology</i> , 2021 , 2, 1-10	0.4	1
103	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021 , 12, 880-889	3.2	13
102	Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy. <i>Cancer Investigation</i> , 2021 , 1-12	2.1	0
101	Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 396-404	3.3	2
100	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
99	Advanced Non-linear Generative Model with a Deep Classifier for Immunotherapy Outcome Prediction: A Bladder Cancer Case Study. <i>Lecture Notes in Computer Science</i> , 2021 , 227-242	0.9	0
98	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
97	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.. <i>Thoracic Cancer</i> , 2021 ,	3.2	2
96	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
95	A BRAF new world. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103008	7	18
94	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , 2020 , 21, 914-922	21.7	328
93	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. <i>Acta Oncologica</i> , 2020 , 59, 1058-1063	3.2	20
92	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27

91	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
90	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020 , 130, 155-167	7.5	53
89	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103036	7	2
88	KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. <i>Cancer Treatment Reviews</i> , 2020 , 85, 101978	14.4	45
87	Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 874	59.2	3
86	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020 , 28, 4687-4695	3.9	6
85	The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2020 , 21, e539-e543	4.9	7
84	Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2020 , 22, 2130-2135	3.6	15
83	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2391-2400	4.4	6
82	Diagnostic test assessment. Validation study of an alternative system to detect microsatellite instability in colorectal carcinoma. <i>Pathologica</i> , 2020 , 112, 178-183	1.9	3
81	Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications. <i>Nutrients</i> , 2020 , 13,	6.7	11
80	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020 , 14, 490	4.3	16
79	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$. <i>Journal of Immunotherapy</i> , 2020 , 43, 299-306	5	10
78	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation 2020 , 8,		29
77	Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial. <i>PLoS ONE</i> , 2020 , 15, e0239803	3.7	13
76	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020 , 25, e1509-e1515	5.7	7
75	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020 , 150, 123-131	5.9	4
74	The METeoric rise of MET in lung cancer. <i>Cancer</i> , 2020 , 126, 4826-4837	6.4	7

73	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1533-1542	4.4	21
72	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 1299	5.3	5
71	3D Non-Local Neural Network: A Non-Invasive Biomarker for Immunotherapy Treatment Outcome Prediction. Case-Study: Metastatic Urothelial Carcinoma. <i>Journal of Imaging</i> , 2020 , 6,	3.1	3
70	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020 , 22, 844-851	3.6	13
69	Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 79	5.4	22
68	Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 95-101	7	4
67	Tumor Mutation Burden-From Hopes to Doubts. <i>JAMA Oncology</i> , 2019 , 5, 934-935	13.4	63
66	Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support. <i>Frontiers in Endocrinology</i> , 2019 , 10, 318	5.7	4
65	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 87-90	7	15
64	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019 , 9, 264	5.3	59
63	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019 , 9, 166	5.3	34
62	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 137, 154-164	7	2
61	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019 , 76, 73-81	10.2	74
60	The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. <i>Frontiers in Medicine</i> , 2019 , 6, 172	4.9	25
59	An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0220988	3.7	12
58	New emerging targets in cancer immunotherapy: the role of TIM3. <i>ESMO Open</i> , 2019 , 4, e000497	6	49
57	Advanced Deep Learning Embedded Motion Radiomics Pipeline for Predicting Anti-PD-1/PD-L1 Immunotherapy Response in the Treatment of Bladder Cancer: Preliminary Results. <i>Electronics (Switzerland)</i> , 2019 , 8, 1134	2.6	12
56	Bio-Inspired Deep-CNN Pipeline for Skin Cancer Early Diagnosis. <i>Computation</i> , 2019 , 7, 44	2.2	5

55	Tumor Mutation Burden-From Doubts to Concerns-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1809	13.4	2
54	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019 , 14, e0224027	3.7	4
53	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019 , 11, 4972-4981	2.6	15
52	Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019 , 21, 107	6.3	27
51	Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. <i>Neuro-Oncology Practice</i> , 2019 , 6, 264-273	2.2	10
50	Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. <i>Clinical and Translational Oncology</i> , 2019 , 21, 790-795	3.6	14
49	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019 , 11,	6.6	222
48	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104	4.9	31
47	Learning from the past to design better trials in second-line treatment for mesothelioma patients. <i>Ecancermedicalscience</i> , 2018 , 12, 881	2.7	
46	The crucial role of predicting brain metastases development in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018 , 10, S3305-S3307	2.6	3
45	Evaluation of Levenberg-Marquardt neural networks and stacked autoencoders clustering for skin lesion analysis, screening and follow-up. <i>IET Computer Vision</i> , 2018 , 12, 957-962	1.4	23
44	Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDia study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
43	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. <i>Anticancer Research</i> , 2018 , 38, 3689-3697	2.3	23
42	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 27-39	7	28
41	Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. <i>BMC Cancer</i> , 2017 , 17, 69	4.8	22
40	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 295-302	4.4	13
39	Consider Quality of Life to Improve Quality of Cancer Guidelines. <i>JAMA Internal Medicine</i> , 2017 , 177, 1537	11.5	1
38	Treatment and prognostic factors of patients with thymic epithelial tumors at first recurrence or progression. <i>Future Oncology</i> , 2017 , 13, 2429-2439	3.6	5

37	Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2017 , 92, 39-47	3.6	17
36	GG: An Overview to Explore the Rationale of Its Use in Cancer. <i>Frontiers in Pharmacology</i> , 2017 , 8, 603	5.6	66
35	Bio-Inspired Feed-Forward System for Skin Lesion Analysis, Screening and Follow-Up. <i>Lecture Notes in Computer Science</i> , 2017 , 399-409	0.9	2
34	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017 , 37, 3723-3728	2.3	3
33	Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. <i>Tumori</i> , 2016 , 102, 108-13	1.7	1
32	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , 2016 , 95, 73-81	5.9	14
31	Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. <i>Journal of Gynecologic Oncology</i> , 2015 , 26, 118-24	4	5
30	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , 2014 , 15, 411-417.e4	4.9	28
29	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014 , 10, 1741-50	3.6	11
28	A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer. <i>Medical Oncology</i> , 2013 , 30, 533	3.7	6
27	Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 390-8	4.9	32
26	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. <i>Anti-Cancer Drugs</i> , 2013 , 24, 99-111	2.4	13
25	Genomic analysis: toward a new approach in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 207-23	7	20
24	Intrasomatic injection of corticosteroid followed by vertebroplasty increases early pain relief rather than vertebroplasty alone in vertebral bone neoplasms: preliminary experience. <i>Skeletal Radiology</i> , 2012 , 41, 459-64	2.7	7
23	Intensified chemotherapy with stem-cell rescue in germ-cell tumors. <i>Annals of Oncology</i> , 2012 , 23, 815-22	20.3	15
22	CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. <i>Cancer Biomarkers</i> , 2011 , 10, 79-89	3.8	24
21	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , 2011 , 73, 78-88	5.9	4
20	Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 50	12.8	19

19	Anticancer oral therapy: emerging related issues. <i>Cancer Treatment Reviews</i> , 2010 , 36, 595-605	14.4	115
18	Combined use of biomarkers for detection of ovarian cancer in high-risk women. <i>Tumor Biology</i> , 2010 , 31, 209-15	2.9	30
17	Thymoma Associated with Myasthenia and Autonomic anti-Hu Paraneoplastic Neuropathy. <i>Tumori</i> , 2009 , 95, 243-247	1.7	15
16	Is a 1-cm margin from major vessels adequate for radiofrequency ablation of pulmonary neoplasms?. <i>Annals of Thoracic Surgery</i> , 2009 , 88, 351-2	2.7	
15	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2008 , 14, 8205-12	12.9	288
14	Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 127-34	4.4	16
13	Cementoplasty in the management of painful extraspinal bone metastases: our experience. <i>Radiologia Medica</i> , 2008 , 113, 1018-28	6.5	51
12	Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. <i>European Journal of Haematology</i> , 2007 , 78, 322-9	3.8	19
11	Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007 , 81, 323-5	4.8	
10	High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. <i>Current Stem Cell Research and Therapy</i> , 2007 , 2, 65-82	3.6	19
9	Trastuzumab in breast cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 640-4; author reply 640-4	59.2	6
8	Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1085-91	4.7	11
7	Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. <i>British Journal of Cancer</i> , 2006 , 94, 1550-2	8.7	4
6	Treatments of AIDS-related Kaposi's sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 53, 253-65-7		45
5	Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. <i>Acta Haematologica</i> , 2004 , 112, 141-7	2.7	9
4	Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2004 , 36, 155-7		8
3	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 171-89	7	18
2	BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. <i>Cancer Treatment Reviews</i> , 2001 , 27, 295-304	14.4	64

- 1 Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. *Cancer Letters*, **2001**, 168, 31-6 9.9 46